Glycycoumarin (C007B-358124)

Glycycoumarin is a potent antispasmodic agent. Glycycoumarin is a major bioactive coumarin of licorice and exhibits antispasmodic activity. Glycycoumarin also has hepatoprotective effect. Glycycoumarin can be used for the research of abdominal pain and liver diseases.In VitroGlycycoumarin, (25 μM; 24 h) combining with ABT-737 (12.5 μM) synergistically, induces cell death in multiple types of liver cancer cell HepG2. Glycycoumarin is highly effective against alcoholic liver disease, nonalcoholic fatty liver disease, acetaminophen-induced hepatotoxicity, and liver cancer through mechanisms involved in activation of Nrf2 antioxidant system, stimulation of AMPK-mediated energy homeostasis, induction of autophagy degradation process, and inhibiting oncogenic kinase T-lymphokine-activated killer cell-originated protein kinase activity. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HepG2, SMMC-7721, and Huh-7 Concentration: 10, 20, 25, 30, and 40 μM Incubation Time: 24 hours Result: Induced cell death in multiple types of liver cancer cell lines in a dose-dependent manner.In VivoGlycycoumarin (30 μM-0.3 nM; 5 min) has an inhibitory effect on smooth muscle contraction induced by various types of stimulants through the inhibition of PDEs, especially isozyme 3, followed by the accumulation of intracellular cAMP ./nGlycycoumarin (10 mg/kg; i.p.; once daily for 4 d) enhances tumor growth inhibition in HepG2 xenograft model in mice and shows synergistical effect with ABT-737 (HY-50907). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male ICR mice (aged 6 weeks, weight 25-30 g) Dosage: 30 μM-0.3 nM, 5 min Administration: Result: Inhibited the contraction induced by various types of stimulants, such as CCh, KCI, BaCI(2), and A23187 (calcium ionophore III). Enhanced the relaxation induced by forskolin on CCh-evoked contraction and also enhances the relaxation effect of rolipram. Associated with dose-dependent accumulation of cAMP. Animal Model: HepG2 cancer cells xenograft model in male BALB/c athymic nude mice (6-7 weeks old)Dosage: 10 mg/kg Administration: Intraperitoneal injection; once daily for 4 days; ABT-737 group was given 100 mg/kg i.p. Result: Inhibited tumor growth and resulted a reduction of the final tumor weight by 17%. Specification: 10mM in DMSO Molecular Formula: C21H20O6 Molecular Weight: 368.38